Atypical ductal hyperplasia: breast DCE-MRI can be used to reduce unnecessary open surgical excision
ConclusionAfter a percutaneous biopsy diagnosis of ADH, malignancy can be ruled out in most of the cases, if no suspicious enhancement is present in the biopsy area at DCE-MRI. Breast DCE-MRI may be used to avoid surgery in more than half of the patients with final benign diagnosis.Key Points• Breast DCE-MRI can safely rule out malignancy if no suspicious enhancement is present in the biopsy area after a percutaneous biopsy diagnosis of ADH.• All cases of upgrade to high-grade DCIS and invasive cancers can be identified at breast DCE-MRI after a percutaneous biopsy diagnosis of ADH.• Breast DCE-MRI may be used to avoid surgery in more than half of the patients with final benign diagnosis.
A new analysis shows that any diagnosis of ductal carcinoma in situ is associated with a long-term risk of invasive breast cancer and that treatment lowers this risk.Medscape Medical News
ah Hosseini The majority of cancer evolution studies involve individual-based approaches that neglect the population dynamics necessary to build a global picture of cancer evolution for each cancer type. Here, we conducted a population-based study in breast cancer to understand the timing of malignancy evolution and its correlation to the genetic evolution of pathological stages. In an omics integrative approach, we integrated gene expression and genomic aberration data for pre-invasive (ductal carcinoma in situ; DCIS, early-stage) and post-invasive (invasive ductal carcinoma; IDC, late-stage) samples and investigated ...
FRIDAY, May 29, 2020 -- Women with cancerous cells in their milk ducts -- also known as DCIS -- are at a high risk for developing fatal breast cancer, British researchers report. DCIS is short for ductal carcinoma in situ, an early form of breast...
(NRG Oncology) The addition of the monoclonal antibody therapy Trastuzumab to radiotherapy did not reach the protocol objective of a 36% reduction in the ipsilateral breast tumor recurrence rate for women with HER2-positive ductal carcinoma in situ (DCIS) on the NRG Oncology clinical trial NSABP B-43. The trial did find a statistically non-significant, modest (19%) reduction in the rate of recurrence among women that received trastuzumab, but this difference was not statistically significant.
In conclusion, preoperatively diagnosed non-mass-type DCIS represented an underestimation in approximately 27% of cases. In particular, the presence of a clinically abnormal palpation increases the chance of upstaging to invasive cancer. PMID: 32454975 [PubMed]
THURSDAY, May 28, 2020 -- Women with screening-detected ductal carcinoma in situ (DCIS) have increased long-term risks for invasive breast cancer and breast cancer death, according to a study published online May 27 in The BMJ. Gurdeep S. Mannu,...
Conclusion: We improved the prediction performance of DCIS upstaging by embedding two related pathology classes in different training phases. Significance: The three new strategies of embedding related class data all outperformed the baseline model, thus demonstrating not only feature similarities among these different classes, but also the potential for improving classification by using other related classes.
CONCLUSION: These findings support the use of prophylactic NSM in high-risk patients. The nipples could be preserved in the majority of patients, postoperative complication rates were low, and, with limited follow-up, there were no new breast cancers. PMID: 32432359 [PubMed - as supplied by publisher]